1	High-risk Escherichia coli clones that cause neonatal meningitis and association with
2	recrudescent infection
3	
4	Nguyen Thi Khanh Nhu ^{1,2,3} , Minh-Duy Phan ^{1,2,3} , Steven J. Hancock ^{2,3#} , Kate M. Peters ^{1,2,3} ,
5	Laura Alvarez-Fraga ^{2,3[^]} , Brian M. Forde ^{3,4} , Stacey B. Andersen ⁵ , Thyl Miliya ⁶ , Patrick N.A.
6	Harris ^{4,7} , Scott A. Beatson ^{2,3} , Sanmarie Schlebusch ^{4,7,8} , Haakon Bergh ⁷ , Paul Turner ^{6,9} ,
7	Annelie Brauner ¹⁰ , Benita Westerlund-Wikström ¹¹ , Adam D. Irwin ^{3,4,12*} , and Mark A.
8	Schembri ^{1,2,3*}
9	
10	¹ Institute for Molecular Bioscience (IMB), The University of Queensland, Brisbane,
11	Queensland, Australia
12	² School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane,
13	Queensland, Australia
14	³ Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane,
15	Queensland, Australia
16	⁴ University of Queensland Centre for Clinical Research, The University of Queensland,
17	Brisbane, Australia
18	⁵ Genome Innovation Hub, The University of Queensland, Brisbane, Australia
19	⁶ Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap,
20	Cambodia.
21	⁷ Pathology Queensland, Health Support Queensland, Australia
22	⁸ Q-PHIRE Genomics and Public Health Microbiology, Forensic and Scientific Services,
23	Coopers Plains, Brisbane, Queensland, Australia
24	⁹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
25	University of Oxford, Oxford, UK

26	^{10}D	epartment of	f Microbiology,	Tumor and	Cell Biology,	Division of	Clinical	Microbiology,
----	----------	--------------	-----------------	-----------	---------------	-------------	----------	---------------

- 27 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- 28 ¹¹ Molecular and Integrative Biosciences Research Programme, University of Helsinki,
- 29 Helsinki, Finland
- 30 ¹² Infection Management Prevention Service, Queensland Children's Hospital, Brisbane,
- 31 *Queensland, Australia.*

32

- 33 [#]Current Address: Wellcome-Wolfson Institute for Experimental Medicine, School of
- 34 Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United

35 Kingdom.

- 36 Current address: INRAE, Univ Montpellier, LBE, 102 Avenue des Etangs, Narbonne 11100,
 37 France.
- 38
- 39 **Running title:** High risk neonatal meningitis *E. coli* clones
- 40 Word count: Text (3493 words), Abstract (249 words).
- 41

42 ***Corresponding authors:**

- 43 Professor Mark Schembri, Institute for Molecular Bioscience, The University of Queensland,
- 44 Brisbane, Queensland 4072, Australia. E-mail: <u>m.schembri@uq.edu.au</u>.
- 45 Dr Adam Irwin, Centre for Clinical Research, University of Queensland, Brisbane,
- 46 Queensland, Australia. Email: <u>a.irwin@uq.edu.au</u>.

47

49 Abstract

50 Neonatal meningitis is a devasting disease associated with high mortality and neurological 51 sequelae. Escherichia coli is the second most common cause of neonatal meningitis (herein 52 NMEC) and the most common cause of meningitis in preterm neonates. Here we investigated 53 the genomic relatedness of a collection of NMEC strains spanning 1974-2020 and isolated 54 from seven different geographic regions. We show NMEC are comprised of strains from 55 diverse sequence types (STs), with ST95 (34.5%) and ST1193 (15.5%) the most common. No 56 single virulence factor was conserved in all strains; however, genes encoding fimbrial 57 adhesins, iron acquisition systems, the K1 capsule, and O antigen types O18, O75 and O2 58 were most prevalent. Antibiotic resistance genes occurred infrequently. We also monitored 59 the infection dynamics in three patients that suffered relapsed infection caused by the original 60 infecting strain despite appropriate antibiotic treatment based on antibiogram profile and 61 resistance genotype. These patients exhibited severe gut dysbiosis. In one patient, the 62 causative NMEC isolate was also detected in the fecal flora at the time of the second 63 infection episode and after treatment. Thus, although antibiotics are the standard of care for 64 NMEC treatment, our data suggests that failure to eliminate the causative NMEC that resides 65 intestinally can lead to the existence of a refractory reservoir that may seed recrudescent 66 infection.

67

68 Key words: *E. coli*, neonatal meningitis, genomics, relapse infection, gut dysbiosis

69 Introduction

70 Neonatal meningitis (NM) is a devastating disease with a mortality rate of 10-15% and severe 71 neurological sequelae including hearing loss, reduced motor skills and impaired development 72 in 30-50% of cases [1-3]. The incidence of disease is highest in low-income countries and 73 occurs at a rate of 0.1-6.1/1000 live births [3]. Escherichia coli is the second most common 74 cause of NM (herein NMEC), after group B Streptococcus (GBS) [4, 5], and the most 75 common cause of meningitis in preterm neonates [5, 6]. Together, these two pathogens cause 76 $\sim 60\%$ of all cases, with on average one case of NMEC for every two cases of GBS [7, 8]. In 77 several countries, NM incidence caused by GBS has declined due to maternal intrapartum 78 antibiotic prophylaxis; however, NM incidence caused by E. coli remains the same [7, 9]. 79 Moreover, NMEC is the main cause of relapsed infections in neonates [10].

80

81 NMEC are categorised genetically using multi-locus sequence typing (ST) or by serotyping 82 based on cell-surface O antigen (O), capsule (K) and flagella (H) antigens. Analysis of 83 NMEC diversity in France revealed ~25% of strains belong to the ST95 clonal complex 84 (STc95) [11], however, a global picture of NMEC epidemiology is lacking. NMEC possess a 85 limited diversity of serotypes, dominated by O18:K1:H7, O1:K1, O7:K1, O16:K1, O83:K1 86 and O45:K1:H7, which together account for >70% of NMEC [12-14]. Notably, ~80% of 87 NMEC express the K1 capsule, a polysaccharide comprising linear homopolymers of $\alpha 2$ -8-88 linked N-acetyl neuraminic acid [12, 15]. Apart from the K1 capsule, specific NMEC 89 virulence factors are less-well defined, though studies have demonstrated a role for S 90 fimbriae [16], the outer membrane protein OmpA [17], the endothelial invasin IbeA [18] and 91 the cytotoxin necrotising factor CNF1 [19] in translocation of NMEC across the blood-brain 92 barrier and pathogenesis. A large plasmid encoding colicin V (ColV), colicin Ia bacteriocins

and several virulence genes including iron-chelating siderophore systems has also been
strongly associated with NMEC virulence [20].

95

96 Despite being the second major NM aetiology, genomic studies on NMEC are lacking, with 97 most reporting single NMEC complete genomes. Here we present the genomic analyses of a 98 collection of 58 NMEC strains isolated from seven different geographic regions over 46 years 99 to understand virulence gene content, antibiotic resistance and genomic diversity. In addition, 100 we provide a complete genome for 18 NMEC strains representing different sequence types, 101 serotypes and virulence gene profiles, thus more than tripling the number of available NMEC 102 genomes that can be used as references in future studies. Three infants in our study suffered 103 relapsed NMEC infection, and we show this was caused by the same strain. We further 104 revealed that patients that suffered relapsed infection had severe gut dysbiosis, and detected 105 the infecting strain in the intestinal microflora, suggesting NMEC colonisation of the gut 106 provides a reservoir that can seed repeat infection.

107

108

109 **Results**

110 Establishment of an NMEC strain collection from geographically diverse locations

A collection of 52 NMEC strains isolated from the blood or cerebrospinal fluid (CSF) of neonates with meningitis was established with the addition of six completely sequenced NMEC genomes available on the NCBI database. This yielded a final set of 58 NMEC strains spanning 1974 to 2020 (Supplementary Table 1). The strains were isolated from seven different geographic locations; Finland (n=17, 29.3%), Sweden (n=14, 24.1%), Australia (n=15, 25.9%), Cambodia (n=7, 12.1%), USA (n=3, 5.2%), France (n=1, 1.7%) and the Netherlands (n=1, 1.7%).

118

119 ST95 and ST1193 are the two major STs of NMEC

120 Phylogenetic analysis was performed on the 58 NMEC strains, with an additional eight well-121 characterised E. coli strains included for referencing (EC958, UTI89, MS7163, CFT073, 122 UMN026, 536, APEC01, MG1655) (Supplementary Table 1). The NMEC strains were 123 diverse, and spanned phylogroups A, B2, C, D and F; the majority of strains were from 124 phylogroup B2 (n=48, 82.8%). Overall, the strains belonged to 22 STs, of which 15 STs only 125 contained one strain. ST95 (n=20, 34.5%) and ST1193 (n=9, 15.5%) were the two most 126 common NMEC STs (Figure 1, Supplementary Table 1). ST95 strains were isolated over the 127 entire study period, while ST1193 strains were more recent and only isolated from 2013. 128 Four strains belonged to ST390 (6.9%), which is part of the STc95. One strain belonged to a 129 novel ST designated ST11637, which is part of the ST14 clonal complex (STc14) that also 130 contains ST1193 (Figure 1, Supplementary Table 1). Strains from other common phylogroup 131 B2 extra-intestinal pathogenic E. coli (ExPEC) lineages, ST131, ST73 and ST69, as well as 132 several STs associated with environmental sources such as ST48 and ST23, were detected in 133 the collection. However, it is notable that the high incidence of NM associated with ST95 and 134 ST1193 does not reflect the broader high prevalence of major ExPEC clones associated with 135 human infections in the publicly available Enterobase database [21] (Supplementary Figure 136 1), suggesting ST95 and ST1193 exhibit specific virulence features associated with their 137 capacity to cause NM.

138

Eighteen NMEC strains were completely sequenced using complementary long-read Oxford
Nanopore Technology, enabling accurate comparison of NMEC genome size, genomic island
composition and location, and plasmid and prophage diversity (Supplementary Table 2).
These strains spanned the diversity in the collection, representing 11 different STs, including

143	two ST1193 strains (one with the dominant O75:H5 serotype and one with an unusual O6:H5
144	serotype), five ST95 strains with different serotypes, and a strain from the novel ST11637.

145

146 Antibiotic resistance in NMEC

147 Antibiotic resistance profiling revealed an overall low level of resistance in the collection. 148 The ST1193 strains contained fluoroquinolone resistance defining mutations in gyrA (S83L 149 D87N) and parC (S80I), as previously described for this lineage [22]. In addition, 77.8% of 150 ST1193 strains (7/9 strains) also harboured at least one gene conferring resistance to 151 aminoglycosides (aac(3)-IId, aadA5, aph(3'')-Ib and aph(6)-Id), trimethoprim (dftA17) and 152 sulphonamides (sul1 and sul2) (Supplementary Figure 2). Six out of the seven strains from 153 Cambodia had more than one antibiotic resistance gene, likely reflecting increased antibiotic 154 resistance rates in this region [23]. Indeed, in addition to gyrA and parC mutations for 155 fluoroquinolone resistance, CAM-NMEC-6 contains 14 antibiotic resistance genes (including 156 resistance to third-generation cephalosporins and carbapenems) and CAM-NMEC-4 contains 157 11 antibiotic resistance genes (Supplementary Figure 2).

158

159 Virulence factors in NMEC

160 The strains exhibited variable distribution of virulence genes previously linked to NMEC 161 pathogenesis. The most prevalent genes were those involved in iron uptake, including the 162 enterobactin (98%), versiniabactin (98%), aerobactin (62%) and salmochelin (55%) 163 siderophore systems, and the heme receptors chuA (93%) and hma (62%) (Figure 1). Also 164 common were the *sitABCD* genes encoding an iron/manganese transporter (98%). The 165 presence of fimbrial and afimbrial adhesins was also diverse. The most prevalent adhesins 166 were type 1 fimbriae (100%), mat (ecp) fimbriae (98%) and the fdeC adhesin (98%). Genes 167 encoding P and S fimbriae were detected in 36% and 22% of NMEC strains, respectively.

168 The most prevalent toxin was the uropathogenic-specific genotoxin usp (83%), which was 169 only found in phylogroup B2 strains. Other toxin genes encoding the serine protease 170 autotransporters Vat (65% prevalence) and Sat (29%), hemolysin (12%) and cytotoxic 171 necrotizing factor-1 (7%) were less prevalent. Other virulence genes included the aslA 172 arylsulfatase (95%), the *iss* lipoprotein (76%) and the *ibeA* invasin (33%). The ColV-plasmid 173 was present in 33% of the strains (Figure 1, Supplementary Table 1). Direct comparison of 174 virulence factors between ST95 and ST1193, the two most dominant NMEC STs, revealed 175 that the ST95 strains contained significantly more virulence factors than the ST1193 strains 176 (Supplementary Table 1, Supplementary Figure 3).

177

178 NMEC comprise a dominant K1 capsule type and a limited pool of O and H serotypes

The capsule type of the NMEC strains was determined by *in silico* typing. K1 was the dominant capsule type in the collection (43/58 strains, 74.1%) (Figure 1). Thirty-four of these strains were available for capsule testing, and we confirmed K1 expression by ELISA in all but two strains (Supplementary Figure 4). Other capsule types included K2, K5 and K14 (Supplementary Table 1). A capsule type could not be resolved for 12 strains, of which eight did not possess a Group II or Group III capsule type based on the absence of the conserved *kpsD* gene (Figure 1, Supplementary Table 1).

186

187 In silico serotypes were also determined. O18 was the most common O type (n=16, 27.6%),

followed by O75 (n=8, 13.9%) and O2 (n=7, 12.1%). The most dominant H types were H7

189 (n=19, 32.8%), H5 (n=13, 22.4%) and H4 (n=9, 15.5%). The most common serotype was

190 O18:H7:K1 (n=14, 24.1%); these strains belonged to the STc95 (nine ST95, four ST390 and

191 one ST416). The second most common serotype was O75:H5:K1 (n=8, 13.8%); six strains

192 from ST1193 possessed this serotype.

193

194 **NMEC** can cause recurrent invasive infection despite appropriate antibiotic treatment

During 2019 – 2020, three patients from which NMEC strains were originally isolated suffered relapsed infection (Figure 1; MS21522, MS21524 and MS22733), providing an opportunity to compare the infecting isolates over time using whole genome sequencing. In all cases, the infecting *E. coli* isolates were susceptible to the therapy, which comprised cefotaxime (50mg/kg/dose 8 hourly), switched to ceftriaxone (100mg/kg/day) to facilitate home parenteral antibiotic administration. Bacterial culture was performed from blood, CSF, urine and/or stool during the infection period (Figure 2).

- 202
- 203 *Patient 1*

204 Patient 1 (0-8 weeks of age) was admitted to the emergency department with fever, 205 respiratory distress and sepsis. The child was diagnosed with meningitis based on a 206 cerebrospinal fluid (CSF) pleocytosis (>2000 white blood cells; WBCs) and a positive blood 207 culture for E. coli (MS21522). Two weeks after completion of a 3-week course of 208 appropriately dosed therapy with third-generation cephalosporins as described above, the 209 child developed similar symptoms of fever and irritability. Lumbar puncture was performed 210 and the CSF culture was positive for E. coli (MS21576). Both the initial blood culture strain 211 and the relapse CSF strain were non-susceptible to ciprofloxacin and gentamycin, and whole 212 genome sequencing revealed they were identical (ST1193 O18:K1:H5; fimH64), with no 213 single nucleotide polymorphisms (SNPs) nor indels (Figure 2A). Unlike the typical ST1193 214 O75 serotype [22], this strain contained a unique O18 serotype. The strain possessed 215 mutations in gyrA (S83L D87N) and parC (S80I), which explain its resistance to 216 ciprofloxacin, as well as a multidrug resistance IncF plasmid containing genes conferring 217 resistance to aminoglycosides (aac(3)-IId, aadA5, aph(3'')-Ib and aph(6)-Id), trimethoprim

218 (*dfrA17*), sulphonamides (*sul1* and *sul2*) and macrolides (*mphA*) (Supplementary Figure 2).

219 Treatment of the relapse was extended to six weeks of intravenous therapy. At follow-up, no

anatomical or immunological abnormality was identified and development is normal.

221

222 *Patient 2*

223 Patient 2 (0-8 weeks of age) presented to the emergency department with a febrile illness. 224 Blood and urine cultures on admission were positive for E. coli. CSF taken 24 hours after 225 treatment revealed pleocytosis (>300 WBCs, >95% polymorphs) but was sterile. The patient 226 completed a 3-week course of appropriately dosed antibiotic therapy with third-generation 227 cephalosporins. In the 6-week period after discharge, the child had several short admissions 228 to hospital, but no infection was identified. At 11 weeks post initial infection, the child was 229 re-admitted to hospital with high fever. CSF cultures were negative and microscopy was 230 normal, but cultures from blood, urine and faeces were all positive for E. coli. Whole genome 231 sequencing revealed that all strains belonged to ST537 O75:H5 (fimH5; STc14). Pairwise 232 comparison of the relapsed isolates showed that the urine and fecal isolates were identical to 233 the original isolate, while the blood isolate contained one nonsynonymous SNP in the *mdoH* 234 gene encoding a glucan biosynthesis glucosyltransferase (T1358G; V453G). This mutation is 235 located in the large cytoplasmic domain of MdoH likely involved in polymerisation of 236 glucose from UDP glucose; the strain exhibited a mucoid colony morphology suggestive of 237 increased colanic acid production. The strains did not possess plasmids nor antibiotic 238 resistance genes. The infant experienced recurrent urinary tract infections with E. coli and 239 other urinary pathogens through infancy despite normal urinary tract anatomy. At follow-up, 240 no other history of invasive infection or identified immunodeficiency were noted, and the 241 child was reported to be developing normally.

242

243 *Patient 3*

244 Patient 3 (0-8 weeks of age) was admitted to the paediatric intensive care unit with fever and 245 seizures. CSF and blood cultured a fully susceptible E. coli. Two weeks after completing a 246 four-week course of appropriate therapy with third-generation cephalosporins, the infant was 247 readmitted to hospital with fever and irritability, with further investigation identifying E. coli 248 in CSF, urine and blood. Three weeks after the completion of the six-week treatment course, 249 the infant experienced a second relapse, with E. coli isolated from both CSF and blood. 250 Whole genome sequencing revealed that all strains were identical and belonged to ST131 251 O25b:K1:H4 (*fimH22*). These strains contained a ColV-virulence plasmid, but did not 252 harbour acquired antibiotic resistance genes. The infant received a further 6-week course of 253 therapy. Imaging studies and immunological work-up were normal. The child exhibited 254 speech delay but no other developmental abnormality was reported at follow-up.

255

256 The gut as a reservoir to seed relapsed infection

257 In all three relapsed patients, the causative isolates were susceptible to third-generation 258 cephalosporins, suggesting the existence of a persistent reservoir that could evade the cidal 259 effect of antibiotic treatment and seed repeat infection. Indeed, the fact that the causative E. 260 *coli* strain was detected from a fecal sample at the time of the relapsed infection in patient 2 261 (day 77 after initial admission), suggests that NMEC could persist in the gut and cause 262 relapsed infection, an observation that has also been reported for uropathogenic E. coli that 263 cause recurrent urinary tract infection [24] and acute pyelonephritis in infants [25]. 264 Therefore, we retrospectively examined available stored fecal samples from patient 2 at 8-265 and 12-week follow-up visits post relapsed infection (days 149 and 174 after initial 266 admission) and patient 3 during treatment and at discharge after the third episode (days 126 267 and 147 after initial admission) using short-read metagenomic sequencing (Figure 3).

268 Although no fecal samples were available for comparative analysis from either patient prior 269 to antibiotic treatment, we observed a low level of diversity in the composition of the 270 microbiome of both patients, consistent with severe dysbiosis. The microbiome of patient 2 271 was dominated by Enterobacter (37.4% relative abundance), Achromobacter (23.4% relative 272 abundance) and *Bacteroides* (22.7% relative abundance) genera at 8-weeks post relapse 273 infection (day 149 after initial admission), and by Bacteroides genera (75.8% relative 274 abundance) at 12-weeks post relapse infection (day 174 after initial admission). The relative 275 abundance of *E. coli* was 2.05% and 4.1% in each of these samples, respectively, and further 276 analysis using StrainGE [26] showed that the strains were most closely matched to the 277 original causative strain MS21524. We further employed complementary long-read 278 metagenomic sequencing to analyse the 8-week post relapse infection sample, which enabled 279 construction of a complete E. coli genome that was identical to the causative ST537 (fimH5) 280 strain (Figure 2, Figure 3; Supplementary Table 3). In the 12-week post relapse infection 281 fecal sample from patient 2, amplicon sequencing targeting *fimH* identified the presence of *E*. 282 *coli* with the same *fimH* type as the causative strain (*fimH5*). Thus, two independent analyses 283 of samples taken 4 weeks apart demonstrated the existence of the E. coli ST537 strain in the 284 intestinal microflora of patient 2. In patient 3, the microbiome was dominated by 285 Enterococcus genera at both time points examined (93% and 97.4% relative abundance). We 286 were unable to detect E. coli by fimH amplicon sequencing and the relative abundance of E. 287 *coli* in these fecal samples was extremely low (<0.01%) based on metagenomic sequencing 288 (Supplementary Table 3). The extensive dysbiosis revealed in this patient is likely an 289 outcome of the three rounds of antibiotic treatment.

290

291 Discussion

In this study, we present a genomic analysis of 58 NMEC strains isolated over 46 years spanning seven different geographic locations and reveal a dominance of ST95 and ST1193 strains. We also provide direct evidence to implicate the gut as a reservoir for relapsed infection in some patients despite appropriate antibiotic treatment.

296

297 The majority of the NMEC strains in our study belonged to phylogroup B2 (82.8%), an 298 observation consistent with other reports [27, 28]. These strains were predominantly from 299 two major STs, ST95 and ST1193. Strains from ST95 form a major clonal lineage 300 responsible for urinary tract and bloodstream infections [29, 30], and were identified 301 throughout the period of investigation. This lineage was also previously shown to cause 302 ~25% of NM cases in France in the period 2004-2015 [11], demonstrating its enhanced 303 capacity to cause disseminated infection in newborns. ST1193, on the other hand, was first 304 identified in 2012 [31], and is the second most common fluoroquinolone-resistant E. coli 305 lineage after ST131 [22, 32]. ST1193 causing NM was first reported in the USA in 2016 [33]. 306 Here, ST1193 accounted for 15.5% of NMEC strains, all of which were isolated from 2013, 307 and was the dominant lineage since this time. This is consistent with a report in China that 308 showed ST1193 was the most common NMEC (21.4%), followed by ST95 (17.9%), between 309 2009-2015 [34]. Concerningly, the ST1193 strains examined here carry genes encoding 310 several aminoglycoside-modifying enzymes, generating a resistance profile that may lead to 311 the clinical failure of empiric regimens such as ampicillin and gentamicin, a therapeutic 312 combination used in many settings to treat NM and early-onset sepsis [35, 36]. This, in 313 combination with reports of co-resistance to third-generation cephalosporins for some 314 ST1193 strains [22, 34], would limit the choice of antibiotic treatments. The dominance of 315 both ST95 and ST1193 in our collection is notable since other widespread E. coli phylogroup

B2 lineages such as ST131, ST73, ST69 and ST12 do not cause similar rates of NM disease. We speculate this is due to the prevailing K1 polysialic acid capsule serotype found in ST95 and the newly emerged ST1193 clone [22, 37] in combination with other virulence factors (Figure 4) and the immature immune system of preterm infants. Understanding the risk of these clones, as well as perinatal transmission and antibiotic resistance patterns, may inform the appropriateness of interventions such as maternal screening or antimicrobial prophylaxis.

322

323 Although reported rarely, E. coli recrudescence in NM patients has been documented in 324 several single study reports [38, 39]. In these reports, infants received appropriate antibiotic 325 treatment based on antibiogram profiling and no clear clinical risk factors to explain 326 recrudescence were identified, highlighting our limited understanding of NM aetiology. Here, 327 we tracked NMEC recurrence using whole genome sequencing in three patients that suffered 328 relapsed infection and demonstrated that the strain causing recrudescence was the same as the 329 original causative strain and susceptible to the initial antibiotic therapy. In one patient 330 (patient 2), we identified the causative strain in the stool at days 77, 149 and 174 after initial 331 detection in the bloodstream, providing direct evidence of persistence in the gut, and 332 implicating this site as a reservoir to seed recurrent infection. This strain belonged to ST537 333 (serotype O75:H5) and belongs to the same clonal complex as ST1193 (i.e. STc14).

334

This study had several limitations. First, our NMEC strain collection was restricted to seven geographic regions, a reflection of the difficulty in acquiring strains causing this disease. Second, we did not have access to a complete set of stool samples spanning pre- and posttreatment in the relapse patients. This impacted our capacity to monitor *E. coli* persistence and evaluate the effect of antibiotic treatment on changes in the microbiome over time. Third, we did not have access to urine or stool samples from the mother of the infants that suffered

341 recrudescence, and thus cannot rule out mother-to-child transmission as a mechanism of 342 reinfection. Regardless, our study describes the genomic diversity of NMEC, highlighting 343 ST95 and ST1193 as the most important clonal lineages associated with this devastating 344 disease. Although antibiotics are the standard of care for NMEC treatment, we show that 345 even when appropriate antibiotics are used, in some cases they do not eliminate the causative 346 NMEC that resides intestinally. Together with associated antibiotic-driven dysbiosis, this 347 reveals a need to consider diagnostic and therapeutic interventions to mitigate the risk of 348 recrudescent infection.

349

350

351 Methods

352 Ethics statement

The study received ethical approval from the Children's Health Queensland Human Research Ethics Committee (LNR/18/QCHQ/45045). Precise patient details have been removed for ethics compliance; additional de-identified details are available from the corresponding author upon request.

357

358 Bacterial strains

359 A collection of 52 NMEC strains isolated from 1974 to 2020 was achieved from Sweden,

360 Finland, Cambodia and Australia. Strains were stored in glycerol at -80°C until use. All

361 strains were cultured in Lysogeny broth. This collection was complemented by the addition

362 of six completely sequenced NMEC genomes available on the NCBI database, namely strains

363 IHE3034, RS218, S88, NMEC58, MCJCHV-1 and CE10.

364

365 **DNA extraction, genome sequencing and analyses**

366 Genome sequencing was performed using paired-end Illumina methodology. Illumina 367 sequencing data were processed by removing adapters and low-quality reads using 368 Trimmomatic v0.36 [40], with a minimum quality score of 10 and minimum read length of 369 50. Trimmed reads were *de novo* assembled using SPAdes v3.12.0 [41] with default 370 parameters. Draft assemblies of the 52 NMEC strains from this study, together with six 371 complete NMEC genomes and eight complete genomes from other characterised E. coli 372 representing different phylogroups, were subjected to phylogenetic analysis using parsnp 373 v1.5.3 [42]. A subset of 18 strains were additionally sequenced using Oxford Nanopore 374 Technology long-read sequencing (Nanopore). Complete NMEC genomes were achieved 375 using a combination of Illumina short-read and Nanopore long-read data and analysis 376 employing the MicroPIPE tool [43].

377

378 *In silico* and molecular analyses

379 Virulence-associated genes, antibiotic resistance genes, plasmids and serotyping were 380 evaluated using ABRicate (https://github.com/tseemann/abricate) with built-in databases [44-381 47], with the percentage nucleotide identity and coverage cut-off set at 90% and 80%, 382 respectively. Capsule typing was performed employing Kaptive [48] using an in-house E. 383 coli capsule database [37] and manually checked. Chromosomal point mutations associated 384 with antibiotic resistance were detected using PointFinder [49]. FimH amplicon sequencing 385 was performed as previously described [50, 51]; allelic variants were identified using 386 FimTyper [52].

387

388 K1 ELISA

K1 capsule expression was detected by ELISA using an anti-polysialic acid antibody single
chain Fv fragment [53] as the primary antibody, anti-His antibody and alkaline phosphatase

anti-mouse IgG as the secondary and tertiary antibodies, respectively; pnitrophenylphosphate (Sigma) was used as the substrate. Optical density was measured at 420
nm.

394

395 Metagenomic sequencing and analyses

Metagenomic sequencing was performed on DNA extracted from fecal samples using the Illumnina NovaSeq6000 platform. Adapters and low-quality reads were trimmed using Trimmomatic v0.36 [40], employing a minimum quality score of 10 and minimum read length of 50. Sequencing reads corresponding to human DNA were discarded by mapping the trimmed reads to the human genome hg38 (accession number GCA_000001405.29) using bowtie2 [54]. Taxonomical profiling was performed with Kraken2 [55] followed by Bracken [56].

403

404 Long-read metagenomic sequencing

405 Long-read metagenomic sequencing was performed on DNA extracted from a fecal sample. 406 A HiFi gDNA library was prepared using the SMRTbell Express Template Prep Kit 2.0 407 (PacBio, 100-938-900) according to the low input protocol (PacBio, PN 101-730-400 408 Version 06 [June 2020]). As the sample DNA was already fragmented with a tight peak 409 (mode size 9.4 kb), no shearing was performed; the sample was concentrated using Ampure 410 PB beads (PacBio, PCB-100-265-900) and used directly as input into library preparation. 411 The entire quantity of purified DNA (360ng) was used to make the library as follows. The 412 DNA was treated to remove single-stranded overhangs, followed by a DNA damage repair 413 reaction and an end-repair/A-tailing reaction. Overhang barcoded adapters were ligated to the 414 A-tailed library fragments, followed by a nuclease treatment to remove damaged library 415 fragments, and then purification with AMPure PB beads. The library was size-selected to

remove fragments <3kb using AMPure PB beads. The final purified, size-selected library was
quantified on the Qubit fluorometer using the Qubit dsDNA HS assay kit (Invitrogen,
Q32854) to assess concentration, and run on the Agilent Femto Pulse using the 55 kb BAC
Analysis Kit (Agilent, FP-1003-0275) to assess fragment size distribution.

420

421 Sequencing was performed using the PacBio Sequel II (software/chemistry v10.1). The 422 library pool was prepared for sequencing according to the SMRT Link (v10.1) sample setup 423 calculator, following the standard protocol for Diffusion loading with Ampure PB bead 424 purification, using Sequencing Primer v5, Sequel II Binding Kit v2.2 and the Sequel II DNA 425 Internal Control v1. Adaptive loading was utilised, with nominated on-plate loading 426 concentration of 80pM. The polymerase-bound library was sequenced on 1 SMRT Cell with 427 a 30-hour movie time plus a 2-hour pre-extension using the Sequel II Sequencing 2.0 Kit 428 (PacBio, 101-820-200) and SMRT Cell 8M (PacBio, 101-389-001).

429

After sequencing, the data was processed to generate CCS reads and demultiplex samples using the default settings of the CCS with Demultiplexing application in SMRT Link (v10.1). The demultiplexed reads were assembled *de novo* using Hifiasm [57]. Assembled contigs were subject to taxonomic profiling using kraken2 [55] and fastANI [58]. Contigs taxonomically assigned as *Escherichia coli* were subjected to *in silico* sequence typing using MLST (https://github.com/tseemann/mlst) and mlst profiles from PubMLST [59].

436

Author Contributions: Conceptualization, MAS, AB, BW-W and ADI.; Investigation,
NTKN, M-DP, SJH, KMP, LA-F, BMF, SBA, and TM.; Formal analysis, NTKN, M-DP,
ADI and MAS., Resources, PNAH, SAB, SS, HB, PT, AB, BW-W, ADI and MAS.; Writing
Original Draft, NTKN, ADI and MAS.; Writing – Review & Editing, All Authors.;

441	Supervision, ADI and MAS.; Funding Acquisition, NTKN, M-DP, PNAH, SAB, SS, PT,
442	ADI, MAS.
443	
444	Declaration of interests: The authors declare that they have no conflict of interest.
445	
446	Data sharing: Genome sequence data have been deposited in the Sequence Read Archive
447	under the BioProjects PRJNA757133 and PRJNA893826. Sample accession numbers are
448	listed in Supplementary Table 4.
449	
450	Acknowledgments
451	The authors would like to thank Michelle Bauer for technical expertise and the laboratories
452	contributing the isolates, Pathology Queensland and Mater Pathology. At the time of the
453	study SS was affiliated with Mater Pathology, South Brisbane, Australia. This work was
454	supported by project grants APP1181958 and APP2001431 (to MAS, MDP and NTKN) and
455	an Investigator grant GNT1197743 (to ADI) from the National Health and Medical Research
456	Council of Australia (NHMRC), a Children's Hospital Foundation Innovator grant (50270, to
457	MAS, ADI, PNAH, SAB and SS), an Australian Infectious Diseases Research Centre grant
458	(to MAS, ADI and NTKN), a grant from the Genome Innovation Hub at the University of
459	Queensland, and a grant from the Wellcome Trust to PT (Grant number 220211). For the
460	purpose of open access, the author (PT) has applied a CC BY public copyright licence to any
461	Author Accepted Manuscript version arising from this submission.
462	

463

464 **References**

- Doctor BA, Newman N, Minich NM, Taylor HG, Fanaroff AA, Hack M. Clinical
 outcomes of neonatal meningitis in very-low birth-weight infants. Clin Pediatr (Phila)
 2001; 40(9): 473-80.
- 4682.Stevens JP, Eames M, Kent A, Halket S, Holt D, Harvey D. Long term outcome of469neonatal meningitis. Arch Dis Child Fetal Neonatal Ed **2003**; 88(3): F179-84.
- 4703.Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective471study of mortality and morbidity. Semin Perinatol **1999**; 23(3): 218-25.
- 4724.Ouchenir L, Renaud C, Khan S, et al. The Epidemiology, Management, and Outcomes473of Bacterial Meningitis in Infants. Pediatrics **2017**; 140(1).
- 474 5. Gaschignard J, Levy C, Romain O, et al. Neonatal Bacterial Meningitis: 444 Cases in 7
 475 Years. Pediatr Infect Dis J **2011**; 30(3): 212-7.
- 4766.Basmaci R, Bonacorsi S, Bidet P, et al. Escherichia Coli Meningitis Features in 325477Children From 2001 to 2013 in France. Clin Infect Dis **2015**; 61(5): 779-86.
- 478 7. May M, Daley AJ, Donath S, Isaacs D, Australasian Study Group for Neonatal I. Early
 479 onset neonatal meningitis in Australia and New Zealand, 1992-2002. Arch Dis Child
 480 Fetal Neonatal Ed **2005**; 90(4): F324-7.
- 481 8. Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales:
 482 10 years on. Arch Dis Child Fetal Neonatal Ed **2001**; 84(2): F85-9.
- 483 9. van der Flier M. Neonatal meningitis: small babies, big problem. Lancet Child Adolesc
 484 Health **2021**; 5(6): 386-7.
- 485 10. Anderson SG, Gilbert GL. Neonatal gram negative meningitis: a 10-year review, with
 486 reference to outcome and relapse of infection. J Paediatr Child Health 1990; 26(4):
 487 212-6.
- 488 11. Geslain G, Birgy A, Adiba S, et al. Genome sequencing of strains of the most
 489 prevalent clonal group of O1:K1:H7 Escherichia coli that causes neonatal meningitis
 490 in France. BMC Microbiol **2019**; 19(1): 17.
- 49112.Sarff LD, McCracken GH, Schiffer MS, et al. Epidemiology of Escherichia coli K1 in492healthy and diseased newborns. Lancet 1975; 1(7916): 1099-104.
- Hainvert C, Bidet P, Peigne C, et al. A new O-antigen gene cluster has a key role in
 the virulence of the Escherichia coli meningitis clone O45:K1:H7. J Bacteriol 2007;
 189.
- 496 14. Bidet P, Mahjoub-Messai F, Blanco J, et al. Combined multilocus sequence typing and
 497 O serogrouping distinguishes Escherichia coli subtypes associated with infant
 498 urosepsis and/or meningitis. J Infect Dis **2007**; 196(2): 297-303.
- 49915.Robbins JB, McCracken GH, Jr., Gotschlich EC, Orskov F, Orskov I, Hanson LA.500Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N501Engl J Med **1974**; 290(22): 1216-20.
- 50216.Prasadarao NV, Wass CA, Hacker J, Jann K, Kim KS. Adhesion of S-fimbriated503Escherichia coli to brain glycolipids mediated by sfaA gene-encoded protein of S-504fimbriae. J Biol Chem 1993; 268(14): 10356-63.
- 50517.Prasadarao NV, Wass CA, Weiser JN, Stins MF, Huang SH, Kim KS. Outer membrane506protein A of Escherichia coli contributes to invasion of brain microvascular507endothelial cells. Infect Immun **1996**; 64(1): 146-53.
- 50818.Huang SH, Chen YH, Kong G, et al. A novel genetic island of meningitic Escherichia509coli K1 containing the ibeA invasion gene (GimA): functional annotation and carbon-

source-regulated invasion of human brain microvascular endothelial cells. Funct

510


511 Integr Genomics **2001**; 1(5): 312-22. 512 19. Wang MH, Kim KS. Cytotoxic necrotizing factor 1 contributes to Escherichia coli 513 meningitis. Toxins (Basel) 2013; 5(11): 2270-80. 514 20. Peigne C, Bidet P, Mahjoub-Messai F, et al. The plasmid of Escherichia coli strain S88 515 (O45:K1:H7) that causes neonatal meningitis is closely related to avian pathogenic E. 516 coli plasmids and is associated with high-level bacteremia in a neonatal rat 517 meningitis model. Infect Immun 2009; 77(6): 2272-84. 518 Zhou Z, Alikhan NF, Mohamed K, Fan Y, Agama Study G, Achtman M. The EnteroBase 21. 519 user's guide, with case studies on Salmonella transmissions, Yersinia pestis 520 phylogeny, and Escherichia core genomic diversity. Genome Res **2020**; 30(1): 138-52. 521 22. Johnson TJ, Elnekave E, Miller EA, et al. Phylogenomic Analysis of Extraintestinal 522 Pathogenic Escherichia coli Sequence Type 1193, an Emerging Multidrug-Resistant 523 Clonal Group. Antimicrob Agents Chemother **2019**; 63(1). 524 23. Reed TAN, Krang S, Miliya T, et al. Antimicrobial resistance in Cambodia: a review. Int 525 J Infect Dis 2019; 85: 98-107. 526 24. Forde BM, Roberts LW, Phan MD, et al. Population dynamics of an Escherichia coli 527 ST131 lineage during recurrent urinary tract infection. Nat Commun **2019**; 10(1): 528 3643. 529 25. Tullus K, Horlin K, Svenson SB, Kallenius G. Epidemic outbreaks of acute 530 pyelonephritis caused by nosocomial spread of P fimbriated Escherichia coli in 531 children. J Infect Dis 1984; 150(5): 728-36. 532 26. van Dijk LR, Walker BJ, Straub TJ, et al. StrainGE: a toolkit to track and characterize 533 low-abundance strains in complex microbial communities. Genome Biol **2022**; 23(1): 534 74. 535 27. Wijetunge DS, Gongati S, DebRoy C, et al. Characterizing the pathotype of neonatal 536 meningitis causing Escherichia coli (NMEC). BMC Microbiol 2015; 15: 211. 537 28. Bidet P, Mahjoub-Messai F, Blanco J, et al. Combined Multilocus Sequence Typing 538 and O Serogrouping Distinguishes Escherichia coli Subtypes Associated with Infant 539 Urosepsis and/or Meningitis. J Infect Dis **2007**; 196. 540 29. Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global Extraintestinal 541 Pathogenic Escherichia coli (ExPEC) Lineages. Clin Microbiol Rev 2019; 32(3). 542 30. Kallonen T, Brodrick HJ, Harris SR, et al. Systematic longitudinal survey of invasive 543 Escherichia coli in England demonstrates a stable population structure only 544 transiently disturbed by the emergence of ST131. Genome Res 2017. 545 31. Platell JL, Trott DJ, Johnson JR, et al. Prominence of an O75 clonal group (clonal 546 complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing 547 extraintestinal infections in humans and dogs in Australia. Antimicrob Agents 548 Chemother 2012; 56(7): 3898-904. 549 Tchesnokova VL, Rechkina E, Larson L, et al. Rapid and Extensive Expansion in the 32. 550 United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence 551 Type 1193. Clin Infect Dis **2019**; 68(2): 334-7. 552 33. Nielsen DW, Ricker N, Barbieri NL, et al. Complete Genome Sequence of the 553 Multidrug-Resistant Neonatal Meningitis Escherichia coli Serotype 075:H5:K1 Strain 554 mcjchv-1 (NMEC-O75). Microbiol Resour Announc 2018; 7(10). 555 34. Ding Y, Zhang J, Yao K, Gao W, Wang Y. Molecular characteristics of the new 556 emerging global clone ST1193 among clinical isolates of Escherichia coli from

557		neonatal invasive infections in China. Eur J Clin Microbiol Infect Dis 2021 ; 40(4): 833-
558		40.
559	35.	Fleiss N, Schwabenbauer K, Randis TM, Polin RA. What's new in the management of
560		neonatal early-onset sepsis? Arch Dis Child Fetal Neonatal Ed 2023 ; 108(1): 10-4.
561	36.	Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. Reviewing the WHO
562		guidelines for antibiotic use for sepsis in neonates and children. Paediatr Int Child
563		Health 2018 ; 38(sup1): S3-S15.
564	37.	Goh KGK, Phan MD, Forde BM, et al. Genome-Wide Discovery of Genes Required for
565		Capsule Production by Uropathogenic Escherichia coli. mBio 2017 ; 8(5).
566	38.	Vissing NH, Monster MB, Nordly S, et al. Relapse of Neonatal Escherichia coli
567		Meningitis: Did We Miss Something at First? Children (Basel) 2021 ; 8(2).
568	39.	Bingen E, Cave H, Aujard Y, et al. Molecular analysis of multiply recurrent meningitis
569		due to Escherichia coli K1 in an infant. Clin Infect Dis 1993 ; 16(1): 82-5.
570	40.	Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
571		sequence data. Bioinformatics 2014 ; 30(15): 2114-20.
572	41.	Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm
573		and its applications to single-cell sequencing. J Comput Biol 2012 ; 19(5): 455-77.
574	42.	Treangen TJ, Ondov BD, Koren S, Phillippy AM. The Harvest suite for rapid core-
575		genome alignment and visualization of thousands of intraspecific microbial genomes.
576		Genome Biol 2014 ; 15(11): 524.
577	43.	Murigneux V, Roberts LW, Forde BM, et al. MicroPIPE: validating an end-to-end
578		workflow for high-quality complete bacterial genome construction. BMC Genomics
579		2021 ; 22(1): 474.
580	44.	Chen L, Zheng D, Liu B, Yang J, Jin Q. VFDB 2016: hierarchical and refined dataset for
581		big data analysis10 years on. Nucleic Acids Res 2016 ; 44(D1): D694-7.
582	45.	Feldgarden M, Brover V, Haft DH, et al. Using the NCBI AMRFinder Tool to Determine
583		Antimicrobial Resistance Genotype-Phenotype Correlations Within a Collection of
584		NARMS Isolates. 2019 : 550707.
585	46.	Carattoli A, Zankari E, Garcia-Fernandez A, et al. In silico detection and typing of
586		plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob
587		Agents Chemother 2014 ; 58(7): 3895-903.
588	47.	Ingle DJ, Valcanis M, Kuzevski A, et al. In silico serotyping of E. coli from short read
589		data identifies limited novel O-loci but extensive diversity of O:H serotype
590		combinations within and between pathogenic lineages. Microb Genom 2016 ; 2(7):
591		e000064.
592	48.	Wyres KL, Wick RR, Gorrie C, et al. Identification of Klebsiella capsule synthesis loci
593		from whole genome data. Microb Genom 2016 ; 2(12): e000102.
594	49.	Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a
595		novel web tool for WGS-based detection of antimicrobial resistance associated with
596		chromosomal point mutations in bacterial pathogens. J Antimicrob Chemother 2017 ;
597		72(10): 2764-8.
598	50.	Willner D, Low S, Steen JA, et al. Single clinical isolates from acute uncomplicated
599		urinary tract infections are representative of dominant in situ populations. mBio
600		2014 ; 5(2): e01064-13.
601	51.	Chen Z, Phan MD, Bates LJ, et al. The urinary microbiome in patients with refractory
602		urge incontinence and recurrent urinary tract infection. Int Urogynecol J 2018 ;
603		29(12): 1775-82.


- 60452.Roer L, Tchesnokova V, Allesoe R, et al. Development of a Web Tool for Escherichia605coli Subtyping Based on fimH Alleles. J Clin Microbiol **2017**; 55(8): 2538-43.
- 60653.Nagae M, Ikeda A, Hane M, et al. Crystal structure of anti-polysialic acid antibody607single chain Fv fragment complexed with octasialic acid: insight into the binding608preference for polysialic acid. J Biol Chem **2013**; 288(47): 33784-96.
- 60954.Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods610**2012**; 9(4): 357-9.
- 61155.Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.612Genome Biol **2019**; 20(1): 257.
- 61356.Jennifer Lu FPB, Peter Thielen, Steven L. Salzberg. Bracken: estimating species614abundance in metagenomics data. PeerJ Computer Science **2017**; 3(e104).
- 615 57. Cheng H, Concepcion GT, Feng X, Zhang H, Li H. Haplotype-resolved de novo
 616 assembly using phased assembly graphs with hifiasm. Nat Methods 2021; 18(2): 170617 5.
- 58. Jain C, Rodriguez RL, Phillippy AM, Konstantinidis KT, Aluru S. High throughput ANI
 analysis of 90K prokaryotic genomes reveals clear species boundaries. Nat Commun
 2018; 9(1): 5114.
- 62159.Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the622population level. BMC Bioinformatics **2010**; 11: 595.
- 623
- 624

625 Figures

626




627 Figure 1. Maximum likelihood phylogram displaying the relationship of the NMEC strains with their 628 associated serotype and virulence factor profile. Non-NMEC strains used in the analysis for 629 referencing are italicized. The phylogram was built and recombination regions removed employing 630 Parsnp, using 185,911 core single nucleotide polymorphisms (SNPs) and NMEC strain IHE3034 as 631 the reference. The scale bar indicates branch lengths in numbers of SNPs. NMEC strains with 632 available complete genomes are bold-italicized, while NMEC strains that were completely sequenced 633 in this study are indicated in bold and marked with an asterisk. The NMEC strains that caused 634 relapsed infection in this study are indicated in red. Branches are colored according to phylogroups: 635 orange, phylogroup F; red, phylogroup C; green, phylogroup A; violet, phylogroup D and blue, 636 phylogroup B2. The presence of specific virulence factors is indicated in dark blue.



637

Figure 2. Infection and treatment profile of patients suffering relapsed infection. Indicated is the hospital admission history of patients, together with the timeline of sample collection, identified *E. coli* isolates and their infection source, and strain identification based on whole genome sequencing, metagenomic sequencing (MetaWGS) or *fimH* amplicon sequencing. Genomic relatedness is indicated based on the number of single nucleotide polymorphisms (SNPs). The time of admission for the initial episode is indicated as Day 0, with subsequent timepoints indicated as days post initial admission. Admission and discharge days are indicated in red and green, respectively.

- 645
- 646




647

Figure 3. Relative abundance of bacterial genera ($\geq 0.01\%$) in the gut microbiome of patient 2 at 8and 12-week follow-up post relapsed infection (days 149 and 174 after initial admission) (A) and patient 3 during treatment and at discharge after the third episode (days 126 and 147 after initial admission) (B).

652

653



654

Figure 4. Summary of key NMEC virulence genes based on genome profiling performed in this

study. Shown are shared virulence genes common to most NMEC, as well as ST95- and ST1193-

657 specific NMEC virulence genes. Figure created with BioRender.com.




Figure S1. Number of human-derived *E. coli* strains from ST95, ST1193, ST38, ST131, ST73, ST10 and ST69 available in the Enterobase database. Strains were stratified based on their year of isolation, spanning the periods before 2000, 2001-2005, 2006-2010, 2011-2015 and 2016-2022.




Figure S2. Antibiotic resistance gene profile of NMEC strains in the collection. The presence of each resistance gene is denoted by black shading.




Figure S3. ST95 NMEC strains contain more virulence factors than ST1193 NMEC strains. (A) The number of virulence genes (grouped as in Fig.1) for each strain within each ST. (B) The number of virulence genes grouped by their functions in ST95 versus ST1193 strains. P-value were calculated using Mann-Whitney two-tailed unpaired test.




Figure S4. K1 capsule production in NMEC. K1 capsule production was detected by ELISA using a monoclonal antibody specific for polysialic acid. Strains with an $OD_{420} > 0.133$ (mean + 3 standard deviations of a negative control *kpsD* mutant; dashed line) were considered positive for K1 capsule production. Data points represent independent biological replicates with horizontal lines as the mean.